Company Encyclopedia
View More
name
Emergent Biosolutions
EBS.US
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections.
1.946 T
EBS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking117/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE13.92%B
    • Profit Margin9.62%B
    • Gross Margin57.16%B
  • Growth ScoreD
    • Revenue YoY-29.91%E
    • Net Profit YoY136.35%A
    • Total Assets YoY-1.14%D
    • Net Assets YoY14.58%A
  • Cash ScoreD
    • Cash Flow Margin1039.39%B
    • OCF YoY-29.91%E
  • Operating ScoreC
    • Turnover0.54C
  • Debt ScoreD
    • Gearing Ratio60.13%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Emergent Biosolutions Marks 10-Year Anniversary Of The U.S. FDA Approval Of Narcan® Nasal Spray And Reinforces Its Commitment To Increasing Naloxone Access

    Emergent BioSolutions Inc :EMERGENT BIOSOLUTIONS MARKS 10-YEAR ANNIVERSARY OF THE U.S. FDA APPROVAL OF NARCAN® NASAL SPRAY AND REINFORCES ITS COMMITMENT TO INCREASING NALOXONE ACCESS

    Reuters·
    US
    EBS
    +3.88%
    Reuters·
    US
    EBS
    +3.88%

    Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board

    Emergent BioSolutions Inc. announced the retirement of Dr. Louis W. Sullivan from its Board of Directors, effective November 14, 2025, after 19 years of service. Dr. Sullivan has served as chair of the compensation committee and as a member of the nominating and corporate governance committee.

    Reuters·
    US
    EBS
    +3.88%
    Reuters·
    US
    EBS
    +3.88%

    Exec. Chairman Colin V. Reed Acquires Common Shares of Ryman Hospitality Properties Inc

    Colin V. Reed, Executive Chairman of Ryman Hospitality Properties Inc., has acquired common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. Ryman Hospitality Properties Inc. published the original content via EDGAR on November 10, 2025.

    Reuters·
    US
    RHP
    -2.63%
    Reuters·
    US
    RHP
    -2.63%

    Emergent BioSolutions (EBS) Is Up 6.5% After Upgraded 2025 Outlook and Strong Q3 Results Has the Bull Case Changed?

    Emergent BioSolutions (EBS) shares rose 6.5% following the company's strong Q3 2025 results, reporting revenue of $231.1 million and net income of $51.2 million. The firm raised its full-year guidance for 2025, driven by growth in NARCAN nasal spray and new contracts. However, concerns remain about the sustainability of revenue streams and the impact of government contract renewals. The outlook anticipates $744.5 million in revenue and $119.6 million in earnings by 2028, reflecting a potential decline in revenue and earnings. Investors are advised to consider the risks alongside the improved short-term profits.

    Simplywall·
    US
    EBS
    +3.88%
    Simplywall·
    US
    EBS
    +3.88%

    Emergent BioSolutions’ Earnings Call Highlights Strong Growth

    Emergent BioSolutions reported strong financial results in its recent earnings call, exceeding revenue expectations with Q3 revenues of $231 million. The company raised its full-year revenue guidance to $775-$835 million and adjusted EBITDA guidance to $195-$210 million. Key growth areas include a 13% increase in naloxone unit volumes and significant international revenue, which now accounts for 34% of medical countermeasure sales. Despite a decline in year-to-date revenues due to past divestitures, Emergent's robust liquidity and positive outlook position it well for future growth.

    Tip Ranks·
    US
    EBS
    +3.88%
    Tip Ranks·
    US
    EBS
    +3.88%
    © 2025 Longbridge｜Disclaimer